Literature DB >> 16415710

Rating the raters: assessing the quality of Hamilton rating scale for depression clinical interviews in two industry-sponsored clinical drug trials.

Nina Engelhardt1, Alan D Feiger, Kenneth O Cogger, Dawn Sikich, David J DeBrota, Joshua D Lipsitz, Kenneth A Kobak, Kenneth R Evans, William Z Potter.   

Abstract

OBJECTIVE: The quality of clinical interviews conducted in industry-sponsored clinical drug trials is an important but frequently overlooked variable that may influence the outcome of a study. We evaluated the quality of Hamilton Rating Scale for Depression (HAM-D) clinical interviews performed at baseline in 2 similar multicenter, randomized, placebo-controlled depression trials sponsored by 2 pharmaceutical companies.
METHODS: A total of 104 audiotaped HAM-D clinical interviews were evaluated by a blinded expert reviewer for interview quality using the Rater Applied Performance Scale (RAPS). The RAPS assesses adherence to a structured interview guide, clarification of and follow-up to patient responses, neutrality, rapport, and adequacy of information obtained.
RESULTS: HAM-D interviews were brief and cursory and the quality of interviews was below what would be expected in a clinical drug trial. Thirty-nine percent of the interviews were conducted in 10 minutes or less, and most interviews were rated fair or unsatisfactory on most RAPS dimensions.
CONCLUSIONS: Results from our small sample illustrate that the clinical interview skills of raters who administered the HAM-D were below what many would consider acceptable. Evaluation and training of clinical interview skills should be considered as part of a rater training program.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415710     DOI: 10.1097/01.jcp.0000194621.61868.7c

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  17 in total

Review 1.  The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?

Authors:  Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

Review 2.  Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

3.  Rater Training for a Multi-Site, International Clinical Trial: What Mood Symptoms may be most Difficult to Rate?

Authors:  Martha Sajatovic; Richa Gaur; Curtis Tatsuoka; Susan De Santi; Nathan Lee; Judith Laredo; Sulabh Tripathi
Journal:  Psychopharmacol Bull       Date:  2011-09-15

4.  Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?

Authors:  Robert E Becker; Nigel H Greig
Journal:  Alzheimers Dement       Date:  2012-03-30       Impact factor: 21.566

Review 5.  Why so few drugs for Alzheimer's disease? Are methods failing drugs?

Authors:  R E Becker; N H Greig
Journal:  Curr Alzheimer Res       Date:  2010-11       Impact factor: 3.498

Review 6.  Lost in translation: neuropsychiatric drug development.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Sci Transl Med       Date:  2010-12-08       Impact factor: 17.956

Review 7.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

8.  Was phenserine a failure or were investigators mislead by methods?

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2012-12       Impact factor: 3.498

9.  Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?

Authors:  Robert E Becker; Nigel H Greig
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

Review 10.  Alzheimer's disease drug development: old problems require new priorities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-12       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.